Faye M. Johnson
The University of Texas MD Anderson Cancer Center, Dartmouth College
Papers
6
Total Citations
196
H-Index
5
About
Dr. Faye M. Johnson is a leading clinician-scientist whose research focuses on optimizing swallowing outcomes and reducing treatment toxicity for patients with oropharyngeal cancer. Her work sits at the critical intersection of head and neck oncology and functional preservation, comparing the long-term effects of primary transoral robotic surgery (TORS) versus nonsurgical therapies like radiation. Dr. Johnson’s landmark 2019 study (87 citations) provided pivotal evidence on dysphagia after TORS with neck dissection, helping to guide personalized treatment decisions. She has also validated the independent benefits of maintaining oral intake and swallowing exercises during radiotherapy (37 citations), directly shaping clinical protocols to prevent feeding tube dependence. Her 2024 prospective registry analysis (11 citations) further challenged historical norms by re-evaluating feeding tube utilization. Beyond swallowing, Dr. Johnson has explored novel therapeutic strategies in lung cancer, investigating next-generation CDK2/9 inhibitors and anaphase catastrophe (49 citations). Her work has been published in high-impact journals including *JAMA Otolaryngology* and *JAMA Oncology*, and she is recognized for her prospective, longitudinal study designs that track patient function over time. Dr. Johnson’s contributions are essential for any researcher or clinician aiming to balance cancer control with quality of life.
Research Focus
Key Achievements
Top Papers
- 1
- 2Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer49 citations · 2016
- 3
- 4
- 5
- 6